Factors associated with the number of drugs in darunavir/cobicistat regimens
| Autor: | Martinez E, Negredo E, Knobel H, Ocampo A, Sanz J, Garcia-Fraile L, Martin-Carbonero L, Lozano F, Gonzalez-Domenech C, Gutierrez M, Montero M, Boix V, Payeras A, Torralba M, Gonzalez-Cordon A, Moreno A, Alejos B, Perez-Elias M, GeSIDA 9316 CODAR Study Grp |
|---|---|
| Rok vydání: | 2020 |
| Zdroj: | The Journal of antimicrobial chemotherapy r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname |
| ISSN: | 0305-7453 |
| Popis: | Background: Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy. Objectives: To assess factors associated with the number of drugs in darunavir/cobicistat regimens. Methods: A nationwide retrospective cohort study of consecutive HIV-infected patients initiating darunavir/cobicistat in Spain from July 2015 to May 2017. Baseline characteristics, efficacy and safety at 48 weeks were compared according to the number of drugs used. Results: There were 761 patients (75% men, 98% were antiretroviral-experienced, 32% had prior AIDS, 84% had HIV RNA = 200 CD4 cells/mm(3)) who initiated darunavir/cobicistat as mono (n=308, 40%), dual (n=173, 23%), triple (n=253, 33%) or four-drug (n=27, 4%) therapy. Relative to monotherapy, triple therapy was more common in men aged |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|